Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized controlled trial

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14005028

Enrollment

Unknown

Registered

2014-07-30

Start date

2014-09-30

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic Fatty Liver Disease

Interventions

perindopril:take the drug of perindopril

telmisartan:take the drug of telmisartan

amlodipine:take the drug of amlodipine

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 18-70 years old patients who were diagnosed with mild-moderate hypertension and NAFLD;The patients did not take ACEIs or ARBs drugs six weeks before the inclusion;Patients agreed to participate in the trial and signed the informed consent.

Exclusion criteria

Exclusion criteria: There are no coexisting causes for chronic liver disease, such as viral, alcoholic,drug-induced and autoimmune liver diseases; Patients with diabetes mellitus; Patients with serious primary diseases; Patients with mental disorder or can not take the medicine regularly; Pregnancy and nursing mothers; Allergic constitution or intolerance to ACEIs or ARBs drugs.

Design outcomes

Primary

Measure	Time frame
Cap value;	—

Secondary

Measure	Time frame
Angiotensin II;IL-18, IL-1 beta;aminotransferase;lipids;HOMA-IR;	—

Countries

China

Contacts

Public ContactSide Liu

liuside2011@163.com+86 020 61641537

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026